Evidence map›Paper›PMID 33537135›Full record

ArticleAnnals of medicine and surgery (2012)2021

Srujana Mohanty, Ashoka Mahapatra

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of medicine and surgery (2012), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. African journal of laboratory medicine · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Srujana MohantyDepartment of Microbiology, All India Institute of Medical Sciences, Bhubaneswar, 751019, Odisha, India.
Ashoka MahapatraDepartment of Microbiology, All India Institute of Medical Sciences, Bhubaneswar, 751019, Odisha, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTigecycline, a new agent against multidrug-resistant (MDR) bacteria, is especially licensed for use in complicated skin and soft tissue and intra-abdominal infections. We aimed to study the recent

methodsConsecutive isolates (56

resultsThe minimum inhibitory concentrations (MICs) of tigecycline ranged from 0.016 to 48 μg/mL, with MIC

conclusionTigecycline remains a viable therapeutic option against MDR isolates, with excellent

Indexed as

Minimum inhibitory concentrationMultidrug-resistant EnterobacteriaceaeSoft tissue infectionTigecycline

Identifiers

PMID33537135
PMCPMC7840812

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.